Several studies have indicated that TGF-β-mediated inhibitory immune microenvironment weakens the ability of PD-L1/PD-1 inhibitors to rebuild anti-tumor immune response, and ultimately leads to the resistance to PD-1/PD-L1 inhibitors (17–19). The gene discussed is PDCD1; the disease is neoplasm.